Get the Stockscreener App
4.06
4.10%
0.16
After Hours:
4.14
0.08
+1.97%
Opus Genetics Inc stock is traded at $4.06, with a volume of 1.06M.
It is up +4.10% in the last 24 hours and down -15.42% over the past month.
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
See More
Previous Close:
$3.90
Open:
$3.88
24h Volume:
1.06M
Relative Volume:
1.30
Market Cap:
$335.22M
Revenue:
$14.20M
Net Income/Loss:
$-49.59M
P/E Ratio:
-4.8196
EPS:
-0.8424
Net Cash Flow:
$-35.25M
1W Performance:
+4.37%
1M Performance:
-15.42%
6M Performance:
+100.99%
1Y Performance:
+339.58%
1-Day Range:
$3.8704
$4.25
1-Week Range:
$3.80
$4.25
52-Week Range:
$0.9011
$5.81
Opus Genetics Inc Stock (IRD) Company Profile
Name
Opus Genetics Inc
Sector
Industry
Phone
248-681-9815
Address
8 DAVIS DRIVE, DURHAM
Compare IRD vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRD
Opus Genetics Inc
|
4.06 | 323.25M | 14.20M | -49.59M | -35.25M | -0.8424 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Opus Genetics Inc Stock (IRD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-30-26 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-16-26 | Initiated | Oppenheimer | Outperform |
| Jan-20-26 | Initiated | BTIG Research | Buy |
| Dec-10-25 | Initiated | B. Riley Securities | Buy |
| Nov-25-25 | Initiated | Piper Sandler | Overweight |
| Oct-29-25 | Initiated | Wedbush | Outperform |
| Oct-16-25 | Initiated | Chardan Capital Markets | Buy |
| Apr-11-25 | Initiated | Craig Hallum | Buy |
| Nov-13-24 | Resumed | H.C. Wainwright | Buy |
View All
Opus Genetics Inc Stock (IRD) Latest News
IRD Reiterated by Citizens -- Price Target Maintained at $11.00 - GuruFocus
Citizens reiterates Opus Genetics stock rating on development strategy By Investing.com - Investing.com Canada
Guggenheim Initiates Coverage Of Opus Genetics (IRD) With “Buy” Rating And $16 Price Target - Insider Monkey
5 Hot Biotech Stocks Under $5 to Buy - Insider Monkey
Opus Genetics (NASDAQ: IRD) registers 2.68M shares for resale by investors - Stock Titan
IRD Initiates Coverage by Guggenheim -- Rating Set to Buy - GuruFocus
Guggenheim Initiates Opus Genetics at Buy With $16 Price Target - Moomoo
Guggenheim Initiates Opus Genetics(IRD.US) With Buy Rating, Announces Target Price $16 - Moomoo
Opus Genetics: The Future Lies In The Success Of The AAV Delivery Platform (NASDAQ:IRD) - Seeking Alpha
IRD Q1 2026 Earnings: Significant Earnings Miss Amid Pre-Revenue Clinical Development StageBalance Sheet Strength - newsline.com
Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts - marketscreener.com
Opus Genetics Slides Ahead of June Test - Bez Kabli
Opus Genetics touts retinal gene therapy pipeline, September BEST1 data catalyst - MSN
Opus Genetics Inc. (IRD) Q1 2026 Earnings: Steep EPS Miss and No Revenue, Yet Stock Climbs $3.81Estimate Dispersion - newsline.com
IRD News | OPUS GENETICS INC (NASDAQ:IRD) - ChartMill
Opus Genetics reports inducement grants under Nasdaq listing rule - marketscreener.com
Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule - TradingView
Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
JonesTrading Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Gene therapy for blindness: Opus Genetics heads to Jefferies 2026 - Stock Titan
Opus Genetics to Present at the 2026 Jefferies Global Healthcare Conference - The Manila Times
Opus Genetics Touts Retinal Gene Therapy Pipeline, September BEST1 Data Catalyst - inkl
Leerink Partners initiates coverage of Opus Genetics (IRD) with outperform recommendation - MSN
IRD Initiates Coverage by Leerink Partners -- Rating 'Outperform' - GuruFocus
Leerink initiates Opus Genetics stock with outperform rating By Investing.com - Investing.com South Africa
Leerink Partners Initiates Opus Genetics(IRD.US) With Buy Rating, Announces Target Price $10 - Moomoo
Leerink initiates Opus Genetics stock with outperform rating - Investing.com
Leerink Partners Initiates Opus Genetics at Outperform With $10 Price Target - marketscreener.com
Foundation Fighting Blindness Retinal Degeneration Fund Sells 1, - GuruFocus
Foundation fighting blindness fund sells $7.4m of Opus Genetics (IRD) stock - Investing.com Nigeria
Opus Genetics (IRD) investor files exit 13D after stake falls under 5% - Stock Titan
Foundation Fighting Blindness fund trims Opus Genetics (IRD) stake with 1.7M-share sale - Stock Titan
Opus Genetics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
IRD: Gene therapy pipeline advances with pivotal data and regulatory milestones expected in 2024 - TradingView
Lifesci Capital Predicts Lower Earnings for Opus Genetics - MarketBeat
Opus Genetics, Inc. (IRD) reports Q1 loss, misses revenue estimates - MSN
LifeSci Capital Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Opus Genetics (NASDAQ:IRD) Cut to Sell at Wall Street Zen - MarketBeat
Nantahala Capital (IRD) reports 4.84M shares; 3.16M exercisable within 60 days - Stock Titan
Perceptive (IRD) group holds 9.99% of Opus Genetics; warrants capped by limit - Stock Titan
Caligan Partners reports 8.5% stake in Opus Genetics (IRD) - Stock Titan
HC Wainwright Lifts Earnings Estimates for Opus Genetics - MarketBeat
Balyasny holds 5.11M shares in Opus Genetics (NASDAQ: IRD), includes warrants - Stock Titan
Cantor Fitzgerald Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Opus Genetics (NASDAQ:IRD) Stock Rating Lowered by Zacks Research - MarketBeat
Opus Genetics (IRD) Projected to Post Quarterly Earnings on Thursday - MarketBeat
A Quick Look at Today's Ratings for Opus Genetics(IRD.US), With a Forecast Between $8 to $11 - Moomoo
IRD Maintained by Citizens -- Price Target Lowered to $11.00 - GuruFocus
Opus Genetics Inc Stock (IRD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Opus Genetics Inc Stock (IRD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| YERXA BENJAMIN R | President |
Apr 23 '26 |
Sale |
5.24 |
7,470 |
39,121 |
711,535 |
| SCHACHLE JOSEPH K | Chief Operating Officer |
Apr 23 '26 |
Sale |
5.22 |
4,697 |
24,519 |
296,084 |
| Zaremba Rabourn Amy | Head of Fin. Quality Assurance |
Apr 23 '26 |
Sale |
5.20 |
1,641 |
8,540 |
188,671 |
| Magrath George | Chief Executive Officer |
Apr 23 '26 |
Sale |
5.22 |
9,511 |
49,647 |
1,741,344 |
| Jayagopal Ashwath | Chief Scientific & Dev. Ofc. |
Apr 23 '26 |
Sale |
5.19 |
7,542 |
39,156 |
509,233 |
| Gagnon Robert E. | Chief Financial Officer |
Apr 23 '26 |
Sale |
5.18 |
7,842 |
40,658 |
592,158 |
2.60%
0.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):